Information Provided By:
Fly News Breaks for March 2, 2020
NEO
Mar 2, 2020 | 07:38 EDT
Raymond James analyst Andrew Cooper raised the firm's price target on NeoGenomics to $32 from $28 and keeps an Outperform rating on the shares following a "reasonably solid" Q4 print and "somewhat mixed' 2020 guidance. Cooper tells investors in a research note that an unusual gap in the Pharma Services project starts in Q1 also makes that quarter look even lower vs. expectations, but is not unheard of in the sometimes lumpy business line, and organic revenue growth for the year is still expected to be at least 20%.
News For NEO From the Last 2 Days
There are no results for your query NEO